Results 21 to 30 of about 3,594 (173)

The SP/NK1R System-Mediated ROS Generation in GBM Cells through Inhibiting Glutaredoxin Protein

Neurology Research International, 2021
Altered redox balance is among the main contributing factors developing glioblastoma multiforme (GBM), a highly aggressive grade IV brain tumor. Neuropeptide substance P (SP) plays a key role in modifying the cellular redox environment by activating the ...
Negeen Mehrabani, Mohammad Reza Vaezi Kakhki, Hossein Javid, Safieh Ebrahimi, Seyed Isaac Hashemy   +4 more
doaj   +1 more source

In Vitro Biological Evaluation of Aprepitant Based ¹⁷⁷Lu-Radioconjugates

Pharmaceutics, 2022
Currently, the search for promising NK1R-positive tumor-targeting radiopharmaceuticals based on the structure of small molecular antagonists of neurokinin-1 receptor can be observed.
Paweł K. Halik, Przemysław Koźmiński, Joanna Matalińska, Piotr F. J. Lipiński, Aleksandra Misicka, Ewa Gniazdowska   +5 more
doaj   +1 more source

Cardioprotective action of aprepitant in a rat model of ischemia-reperfusioninduced myocardial injury: role of PI3K-AkT-GSK-3β-HIF-1α signaling pathway

Acta Cirúrgica Brasileira, 2022
Purpose: The present study explored the role and mechanism involved in aprepitant-induced cardioprotective effects in rat model of ischemia-reperfusion injury.
Mei Qian, Yang Liu
doaj   +1 more source

Utility of Aprepitant in the Management of Pediatric Patients with Cyclical Vomiting Syndrome

Medicines
Introduction: Cyclical vomiting syndrome (CVS) is a recurrent debilitating illness characterized by intense episodes of nausea and emesis with widely varied pharmacological management across the country.
Aravind Thavamani, Sindhoosha Malay, Jasmine Khatana, Sujithra Velayuthan, Senthilkumar Sankararaman   +4 more
doaj   +1 more source

Identification of optimal contemporary antiemetic prophylaxis for doxorubicin-cyclophosphamide chemotherapy in Chinese cancer patients: post-hoc analysis of 3 prospective studies

Cancer Biology & Medicine, 2021
Objective: Chemotherapy-induced nausea and vomiting (CINV) are common with doxorubicin-cyclophosphamide (AC) chemotherapy. Recommended antiemetic regimens incorporate neurokinin-1 receptor antagonist (NK1RA), 5-hydroxytryptamine type-3 receptor ...
Winnie Yeo, Leung Li, Thomas KH Lau, Kwai T Lai, Vicky TC Chan, Kwan H Wong, Christopher CH Yip, Elizabeth Pang, Maggie Cheung, Vivian Chan, Carol CH Kwok, Joyce JS Suen, Frankie KF Mo   +12 more
doaj   +1 more source

Effect of Aprepitant on Chemotherapy-induced Adverse Reactions in Gynecological Malignancy Patients

Zhongliu Fangzhi Yanjiu, 2018
Objective To observe the curative effect of aprepitant on chemotherapy-induced nausea and vomiting(CINV) and hemoglobin level in gynecological malignancy patients.
HE Yang, YANG Runfeng, ZHOU Yingying, XU Qian, YAN Hao, JIANG Lei, JIANG Xiaohui, HUANG Yi   +7 more
doaj   +1 more source

Single‐dose NEPA versus an aprepitant regimen for prevention of chemotherapy‐induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy

Cancer Medicine, 2023
Introduction Non‐inferiority of NEPA (fixed combination of NK1 receptor antagonist (RA), netupitant, and 5‐HT3RA, palonosetron) versus an aprepitant regimen was previously shown in a pragmatic study in patients receiving anthracycline cyclophosphamide ...
Laurent Zelek, Rudolph Navari, Matti Aapro, Florian Scotté   +3 more
doaj   +1 more source

The effect of mild and moderate hepatic impairment on the pharmacokinetics, safety and tolerability of balcinrenone

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Balcinrenone (previously AZD9977) is a novel selective non‐steroidal mineralocorticoid receptor antagonist (MRA) with a differential mechanism of action relative to approved MRAs. The aim of this trial was to assess the pharmacokinetics, safety and tolerability of balcinrenone in participants with mild and moderate hepatic impairment ...
Anna L. Eriksson, Deeyen Karsanji, Bonifride Tuyishimire, Joanna Parkinson, Maria Heijer, Tadeusz Pawlik, Judith Hartleib‐Geschwindner, Maria Leonsson‐Zachrisson, Hans Ericsson   +8 more
wiley   +1 more source

Stability of Aprepitant Injectable Emulsion in Alternate Infusion Bags, in Refrigerated Storage, and Admixed with Dexamethasone and Palonosetron

Drug Design, Development and Therapy, 2021
Thomas Ottoboni, 1 Laura Lerner, 1 Arlene Santhouse 2 1Pharmaceutical and Translational Science, Heron Therapeutics, Inc, San Diego, CA, USA; 2Medical Affairs, Heron Therapeutics, Inc, San Diego, CA, USACorrespondence: Thomas OttoboniPharmaceutical and
Ottoboni T, Lerner L, Santhouse A
doaj  

Need for Flexible Adjustment of the Treatment Schedule for Aprepitant Administration against Erlotinib-Induced Refractory Pruritus and Skin Rush

Case Reports in Oncology, 2019
Common dermatological side-effects associated with erlotinib, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), include pruritus and skin rash, which are mediated by substance P, leading to the occasional discontinuation of cancer ...
Nobuhiko Seki, Ryosuke Ochiai, Terunobu Haruyama, Masashi Ishihara, Maika Natsume, Yoko Fukasawa, Takahiko Sakamoto, Shigeru Tanzawa, Ryo Usui, Takeshi Honda, Shuji Ota, Yasuko Ichikawa, Kiyotaka Watanabe   +12 more
doaj   +1 more source